Materials and Methods microRNA Prediction Tools
To identify miRNAs targeting EZH2, we integrated the output results of multiple prediction programs; TargetScan (4) . Each program was selected to leverage the various strengths for predicting miRNA targets in the areas of sequence alignment, thermodynamics, and comparative genomics. TargetScan requires a perfect seed, a sub-region of alignment between the miRNA and mRNA, while incorporating traditional RNA folding calculations and conservation of the binding site across vertebrates. PicTar, while preferring a perfect seed match, tolerates imperfect seed matches when they simultaneously adhere to heuristically defined thermodynamic requirements. miRanda employs a dynamic programming algorithm to establish miRNA:mRNA sequence alignment in addition to thermodynamics and conservation across multiple species. Lastly, microInspector identifies possible binding sites within an mRNA sequence relying heavily on free energy values at a binding site. We developed a Perl script that imported the various output formats from each of the target prediction programs and subsequently integrated the results to detect common overlaps. For instance where all programs report an miRNA:mRNA interaction, the candidate miRNAs are sorted based on the predefined rankings from each respective program. Additionally, we export the number of predicted binding sites for miR-101 in the EZH2 3'UTR.
Cell Lines
Breast cancer cell line SKBr3 were grown in RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% FBS (Invitrogen) in 5% CO 2 cell culture incubator, and prostate cancer cell line DU145 were grown in MEM with 10% FBS in 5% CO 2 cell culture incubator. Immortalized breast cell lines HME and H16N2 were grown in F-12 Nutrient Mixture with 5ug/ml Insulin (Sigma,), 1ug/ml Hydrocortisone(Sigma), 10ng/ml EGF (Invitrogen), 5mM Ethanolamine (Sigma) , 5ug/ml Transferrin (Sigma), 10nM Triiodo Thyronine (Sigma), 50nM Sodium Selenite (Sigma), 10mM HEPES (Invitrogen) and 50 unit/ml Penstrep (Invitrogen), 10% CO 2 . For mir-101 overexpression, pMIF-cGFP-Zeo construct expressing mir-101 was obtained from System Biosciences (Mountain View, CA). Lentiviruses were generated by the University of Michigan Vector Core. Prostate cancer cell line DU145 and breast cancer cell line SKBR3 were infected with lentiviruses expressing mir-101 or vector only, and stable cell lines were generated by selection with 300 ug/ml zeocin (Invitrogen, Carlsbad, CA). To generate stable EZH2 knockdown, shRNA lentiviral particles for EZH2 gene silencing and control vector were obtained from SigmaAldrich (St. Louis, MO). Prostate cancer cell line DU145 was infected with EZH2 shRNA lentivirus and a stable cell line was generated by selection with 1 ug/ml Puromycin (Sigma-Aldrich, St. Louis, MO).
Tissues
In this study we utilized tissues from clinically localized prostate cancer patients, who underwent radical prostatectomy as a primary therapy between 2004-2006 at the University of Michigan Hospital, androgen-independent metastatic prostate cancer patients from a rapid autopsy program described previously (5, 6) , and patients with invasive carcinomas of the breast. The detailed clinical and pathological data were maintained on a secure relational database. This study was approved by the Institutional Review Board at the University of Michigan Medical School. Both radical prostatectomy series and the rapid autopsy program were part of the University of Michigan Prostate Cancer Specialized Program of Research Excellence Tissue Core. Breast cancer tissues were collected with IRB approval from the University of Singapore/National University Hospital, Singapore (NUS/NUH). The gastric cancer samples were collected with IRB approval from the National Cancer Center, Singapore.
microRNA Transfection, AntagomiR transfection, and small RNA interference Knockdown of EZH2 was accomplished by RNA interference using siRNA duplex (Dharmacon, Lafayette, CO) as previously described (7) . Precursors of respective microRNAs and negative controls used in this study were purchased from Ambion (Austin, TX). AntagomiR-101 and negative control antagomiRs were purchased from Dharmacon. Transfections were performed with oligofectamine or lipofectamine (Invitrogen) depending on the cell line used.
miR Reporter Luciferase Assays
The 3'UTR (untranslated region) or the antisense sequence of the 3'UTR of EZH2 as well as mutant 3'UTR of EZH2 were cloned into the pMIR-REPORT™ miRNA Expression Reporter Vector (Ambion). SKBr3 cells were transfected with pre-miR-101 or controls and then co-transfected with 3'-UTR-luc or mutant 3'UTR-luc, as well as pRL-TK vector as internal control for luciferase activity. Post 48 hours of incubation, the cells were lysed and luciferase assays conducted using the dual luciferase assay system (Promega, Madison, WI). Each experiment was performed in triplicate.
Quantitative Real-Time PCR Assays
Total RNA was isolated from SKBr3 and DU145 cells that were transfected either with pre-miR-101, or control precursors (Qiagen). Quantitative PCR (QPCR) was performed using SYBR Green dye on an Applied Biosystems 7300 Real Time PCR system (Applied Biosystems, Foster City, CA) as described (5) . Briefly, 1 µg of total RNA was reverse transcribed into cDNA using SuperScript III (Invitrogen, Carlsbad, CA) in the presence of random hexamers and oligo dT primers (Invitrogen). All reactions were performed in triplicate with SYBR Green Master Mix (Applied Biosystems) plus 25 ng of both the forward and reverse primer according to the manufacturer's recommended thermocycling conditions, and then subjected to melt curve analysis. Threshold levels for each experiment were set during the exponential phase of the QPCR reaction using Sequence Detection Software version 1.2.2 (Applied Biosystems). The DNA in each sample was quantified by interpolation of its threshold cycle (C t ) value from a standard curve of C t values, which were created from a serially diluted cDNA mixture of all samples. The calculated quantity of the target gene for each sample was divided by the average sample quantity of the housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to obtain the relative gene expression. All oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA). The primer sequences for the transcript analyzed are provided in table S4.
For microRNA quantitative PCR, total RNA including small RNA was isolated from prostate tissues, SKBr3 and DU145 cells that were transfected either with pre-hsa-miR-101 (precursor human miRNA-101), or control precursors. Total RNA was used at 10ng/ul. For RT, master mix were prepared using 0.15ul 100mM dNTPs, 1.00ul MultiScrible Reverse Transcriptase (50U/ul), 1.50ul 10X Reverse Transcription Buffer, 0.188ul RNase Inhibitor (20U/ul) and 4.192ul Nuclease-free water. Each 15ul RT reaction mix contained, 7ul of master mix, 5ul of RNA samples (10ng/ul) and 3ul 5X specific RT primer. Thermal cycler was programmed as follows: 16 degrees for 30 minutes, 42 degrees for 30 minutes and 85 degrees for 5 minutes. Each PCR reaction mix contained 10 ul of Taqman 2X Universal PCR Master Mix (No AmpErase UNG), 6.67ul Nuclease-free water, 1ul 20X specific PCR primer and 1.33ul RT product. Thermal cycler was programmed as follows: 95 degrees for 10 minutes, 40 cycles of 95 degrees for 15seconds and 60 degrees for 60seconds. Using the comparative CT method, we used endogenous control (RNU6B) to normalize the expression levels of target micro-RNA by correcting differences in the amount of RNA loaded into qPCR reactions.
Genomic PCR Assays
Genomic DNA from benign (n=15), localized prostate cancer (n=16) and metastatic (n=33) prostate cancer tissues were isolated. DNA from benign (n=7), tumor (n=29) and metastatic (n=1, three different sites) from breast cancer cases were also isolated. For genomic analyses of the miR-101 loci, the 2^-∆∆Ct method was adapted using SyBr green based quantitative PCR (qPCR) (8, 9) . Briefly, 100ng 25ng of gDNA was used as template to amplify the miR-101-1, miR-101-2 and miR-217 encompassing loci. Since miR-217 levels did not show significant correlation with EZH2 transcript levels, miR-217 was used as the reference for relative quantification. The assay was validated using the methods described (8, 9) . For unification of data and to avoid inter-assay differences Ct values for the reference gene (miR-217) were always estimated simultaneously with miR-101-1 or miR-101-2. A representative benign tissue sample was used in every assay as a calibrator sample to which every sample was compared, to obtain a relative quantitation (RQ) value. To calibrate the extent of loss in the miR-101 loci we determined the relative levels of 9 different genomic regions on X-chromosome (three regions in phosphoglycerate kinase 1 (PGK1) gene, and six X-chromosome specific miRNAs-miR-424, miR-503, miR-766, miR-448, miR-222 and miR-221) in the genomic DNA from a normal male sample (1X) as compared to a normal female sample (2X) genomic DNA (Promega) that are located only on the X chromosome. RQ values for these regions in male genomic DNA were assessed using a non-Xchromosome gene Tata Binding Protein (TBP) gene as the reference gene (9) . An RQ value of 0.7 and below was considered as loss of at least one copy of the genomic loci (Table S5) , similar to earlier reports (8, 9) . Accordingly, samples showing values lower than 0.7 were considered to have a hemizygous loss and those below 0.3 were considered to exhibit a homozygous loss. For the loss of heterozygosity (LOH) analysis, 9 cancer samples showing miR-101-1 deletion were identified and normal (non prostatic) tissues from the same cases were obtained. Genomic qPCR analysis was carried out in these as described above and RQ values obtained were compared to those obtained from the matched cancer cases. Primer sequences used for genomic PCR assays are given in Table S6 .
Immunoblot Analyses
The breast cancer cell lines SKBr3 and prostate cancer cell DU145 were transfected with pre-miR-101 or controls. The breast cell lines H16N2 and HME were transfected with antagomiR-101 or negative controls. Post 72 hours transfection, cells were homogenized in NP40 lysis buffer (50 mM Tris-HCl, 1% NP40, pH 7.4, Sigma, St. Louis, MO), and complete proteinase inhibitor mixture (Roche, Indianapolis, IN). Ten micrograms of each protein extract were boiled in sample buffer, separated by SDS-PAGE, and transferred onto Polyvinylidene Difluoride membrane (GE Healthcare, Piscataway, NJ). The membrane was incubated for one hour in blocking buffer [Tris-buffered saline, 0.1% Tween (TBS-T), 5% nonfat dry milk] and incubated overnight at 4ºC with the following: anti-EZH2 mouse monoclonal (1:1000 in blocking buffer, BD Biosciences Cat # 612667, San Jose, CA), anti-EED rabbit polyclonal (1:1000, Santa Cruz Biotech, Cat #: sc-28701, Santa Cruz, CA), anti-SUZ12 mouse monoclonal (1:1000, Upstate, Cat #: 04-046, Charlottesville, VA), and anti-N-myc rabbit polyclonal antibodies (1:1000, Cell Signaling Tech, Cat #: 9405, Danvers, MA), anti-ARID1A mouse monoclonal antibody (1:1000, Abcam, Cat #: ab50878, Cambridge, MA), anti-FBN2 rabbit polyclonal antibody (1:1000, Abcam, Cat #: ab21619), anti-c-Fos mouse monoclonal antibody (1:1000, BD Biosciences, Cat #: 554156), antitrimethyl-H3K27 rabbit polyclonal (1:2000, Upstate, Cat #: 07-449), anti-monomethyl-Histone H3 (Lys27) (1:1000 upstate Cat #: 07-448), anti-acetyl-Histone H3 (K27) (upstate Cat #: 07-360) and antitotal Histone H3 rabbit polyclonal (1:5000, Cell Signaling, Cat #: 9715) and anti-GAPDH mouse monoclonal antibody (1:10000, Abcam, Cat #: ab9482). Following a wash with TBS-T, the blot was incubated with horseradish peroxidase-conjugated secondary antibody and the signals visualized by enhanced chemiluminescence system as described by the manufacturer (GE Healthcare).
Cell Proliferation Assay
Cells were plated in 24-well plates at desired cell concentration and transfected with precursor microRNA or controls. Cell counts were estimated by trypsinizing cells and analysis by Coulter counter (Beckman Coulter, Fullerton, CA) at the indicated time points in triplicate.
Cell Migration Assay Using Wound Healing Assay
DU145 lenti-vector and miR-101 overexpressing, and sh-vector and EZH2 knockdown stable cells were grown to confluence. An artificial wound was created using a 1ml pipette tip on confluent cell monolayer. To visualize migrated cells and wound healing, cell images were taken at 0, 24, 48 and 72hrs.
Basement Membrane Matrix Invasion Assays
For invasion assays, the breast cell lines H16N2 and HME were transfected with antagomiR-101 or negative controls. Invasive breast cancer cell SKBr3 and prostate cancer cell DU145 were transfected with pre-miR-101 or controls. Forty-eight hours post-transfection, cells were seeded onto the basement membrane matrix (EC matrix, Chemicon, Temecula, CA) present in the insert of a 24 well culture plate. Fetal bovine serum was added to the lower chamber as a chemoattractant. After 48 hours, the noninvading cells and EC matrix were gently removed with a cotton swab. Invasive cells located on the lower side of the chamber were stained with crystal violet, air dried and photographed. For colorimetric assays, the inserts were treated with 150 µl of 10% acetic acid and the absorbance measured at 560nm using a spectrophotometer (GE Healthcare).
Soft Agar Colony Formation Assays
A 50μL base layer of agar (0.6% Agar in DMEM with 10% FBS) was allowed to solidify in a 96-well flat-bottom plate prior to the addition of a 75μL wild type DU145, DU145 miR-101 clones or vector transfected DU145 cell suspension containing 4,000 cells in 0.4% Agar in DMEM with 10% FBS. The cell containing layer was then solidified at 4C for 15 minutes prior to the addition of 100μL of MEM with 5% FBS. Colonies were allowed to grow for 21 days before imaging under a light microscope.
Prostate Tumor Xenograft Model
All procedures involving mice were approved by the University Committee on Use and Care of Animals (UCUCA) at the University of Michigan and conform to their relevant regulatory standards. Five-weekold male nude athymic BALB/c nu/nu mice (Charles River Laboratory, Wilmington, MA) were used for examining the tumorigenicity. To evaluate the role of miR-101 overexpression in tumor formation, the DU145 stable cells overexpressing miR-101 or vector control cells were propagated and 5x10 6 cells were inoculated subcutaneously into the dorsal flank of ten mice (n = 5 per group). Tumor size was measured every week, and tumor volumes were estimated using the formula (π/6) (L × W 2 ), where L = length of tumor and W = width.
Chromatin Immunoprecipitation (ChIP) Assays
The effect of miR-101 over-expression on trimethyl H3 (Lys-27) status of EZH2 targets was determined by Chromatin Immunoprecipitation (ChIP) assay. The ChIP assay was carried out with antibodies against trimethyl H3 (Lys-27) (Mouse monoclonal from Abcam, Cat: Ab6002-100). The assay was performed using the EZ-Magna ChIP kit (Millipore) according to the manufacturer's protocol. Briefly, 2 × 10 6 cells were used for each immunoprecipitation. The cells were cross-linked for 10 minutes by addition of formaldehyde to a final concentration of 1 %. The cross-linking was stopped by 1/20V of 2.5M glycine. This was followed by cell lysis and sonication, resulting in an average fragment size of 500 bp. Antibody incubations were carried out over-night at 4°C. Reversal of cross-linking was carried out at 65°C for 3 hours, followed by DNA isolation. The purified DNA was analyzed by quantitative PCR to determine fold enrichment relative to input DNA. The primer sequences for the promoters analyzed are provided in Table S7 .
Gene Expression Profiling
Expression profiling was performed using the Agilent Whole Human Genome Oligo Microarray (Santa Clara, CA) according to the manufacturer's protocol. SKBr3 cells were transfected with pre-miR-101 or negative control for precursor microRNA. Over-and under-expressed signatures were generated by filtering to include only features with significant differential expression (Log ratio, P < .01) in all hybridizations and two-fold average over-or under-expression (Log ratio) after correction for the dye flip. To ensure that we were comparing robust gene expression alterations, we analyzed biological replicates and used only the probes showing expression changes in both replicates.
Array Comparative Genomic Hybridization
Comparative genomic hybridization analysis for prostate, breast and gastric cancers were carried using oligonucleotide based comparative genomic hybridization array (Hg17 genome build) (Agilent Technologies, USA) according the manufacture's instructions. Competitive hybridization of differentially labeled tumor and reference DNA to oligonucleotide printed in an array format and analysis of fluorescent intensity for each probe will detect the copy number changes in the tumor sample relative to normal reference genome. We analyzed copy number changes for miR-101-1 ( 1p31.3) and miR-101-2 (9p24.1) regions with a change in copy number level of at least one copy (log ratio ± 0.5) for losses involving more than one probe representing each genomic interval as detected by the aberration detection method (ADM-2) in CGH analytics software 3.5 ( Agilent Technologies) algorithm.
Analysis of Publicly Available Array CGH/SNP Datasets for miR-101 Copy Number Analysis
To examine the mir-101 loss status in multiple cancers, we collected the public array CGH/SNP datasets from Gene Expression Omnibus (http://www.ncbi.nih.gov/geo) and Cancer Bioinformatics Grid (https://cabig.nci.nih.gov/). Acute lymphoblastic leukemia (10), glioblastoma (Data from TCGA) and lung cancer (11) studies were analysed. The sample information was manually curated and classified into cancer (primary plus metastasis), metastasis and normal samples.
For the Affymetrix SNP arrays, model-based expression was performed to summarize signal intensities for each probe set, using the perfect-match/mismatch (PM/MM) model. For copy number inference, raw copy number was calculated by comparing the signal intensity of each SNP probe set for each tumor sample against a diploid reference set of samples. All of the resulting DNA copy number ratios were transformed by log 2. In the two-channel array CGH datasets, the differential ratio between the processed testing channel signal and processed reference channel signal were calculated and transformed by log 2, which reflects the DNA copy number difference between the testing channel and reference channel.
In the normalization step, the log ratios were transformed into a normal distribution with a mean of 0 under the null model assumption. The data were segmented by circular binary segmentation (CBS) algorithm developed by Olshen et al, (12) a method for identifying all genomic change points where the mean log ratio score changes between intervals. The threshold for deletion was modified from the report by Mullighan et al, (10) . Cutoffs of 0.9 and 0.3 were used to identify hemizygous and homozygous deletions, respectively. The probe closest to the selected gene was used to represent the DNA copy number status of this gene, with a maximal distance of 10kb.
Statistical Analyses
All gene expression and relative quantification data were analyzed on the log (base 2) scale. Comparisons between gene expression values across sample classes were made using two-sample Student's t-test. The significance of associations between EZH2 and miR-101 expression values was judged via a test statistic based on Pearson's product moment correlation coefficient. Associations between binary variables (loss at the two miR-101 loci, and overlap of gene sets) were explored using Fisher's exact test. The relationship between EZH2 overexpression and miR-101 loss was evaluated using a test statistic calculated as the minimum observed value of EZH2 expression in the set of samples exhibiting miR-101 loss at either locus. The null permutation distribution of this statistic was derived by randomly permuting miR-101 loss status within the set of samples; N=10000 permutations were used.
The significance of the separation between miR-101 and vector trajectories in the mouse xenograft model was evaluated via a linear mixed model that incorporated a random intercept for each mouse and used square-root transformed tumor volume measurements as dependent variable. Wald tests were used to assess the statistical significance of observed differences between growth rates in the two groups of mice.
All statistical tests were two-sided and constructed at the α=0.05 significance level except for the abovedescribed permutation test, which was one-sided and conducted at the α=0.025 significance level. Statistical analyses were performed using R, version 2.7.0 (http://www.r-project.org).
Supplementary Results and Discussion
To extend our findings of miR-101 deletion to other solid tumors, we first examined breast cancers and found that 6 of 29 breast cancers exhibited loss of miR-101-1 (fig. S17). We had a single breast cancer metastasis, and interestingly, all 3 samples from this patient had marked copy number loss in the miR-101-1 locus. Genomic PCR of the miR-101-2 locus did not produce a significant number of breast cancers exhibiting loss. As EZH2 has been shown to be elevated in a wide variety of cancers (7, (13) (14) (15) (16) (17) (18) (19) , we examined whether miR-101 genomic loss was similarly prevalent across cancer types. In addition, we wanted to complement our genomic PCR assessments with other approaches to measure copy number loss (i.e., array CGH and Affymetrix SNP arrays). We compiled Agilent array CGH data for the region flanking the miR-101 from prostate, breast, and gastric cancer from our group ((tables S8-10 and fig. S15, 16 ). In our prostate cancer Agilent array CGH dataset 22.7% (18/79) tumors exhibited complete loss or loss of heterozygosity of the miR-101 locus and 48.5% (16/33) of metastatic disease showed genomic loss of miR-101. Agilent breast cancer array CGH dataset (n=40), showed 60% of cancers with miR-101 loss, either complete deletion of loss of heterozygosity. Gastric cancer array CGH data indicated 56.2% (36/64) cases with miR-101 loss.
Furthermore, we interrogated published data and publicly available data from The Cancer Genome Anatomy (TCGA) project. Examining the glioblastoma multiforme dataset (n=145) from the TCGA it was observed that 18.7% of cases exhibit loss of miR-101. In a lung adenocarcinoma dataset (11) by Zhao et al (n=63), 37.3% of the cases exhibited loss of the miR-101.
Of note, one of the most extensive studies represented in our meta-analysis (based on genomic coverage and number of patients) was by Mullighan et al, (10) which used 500K Affymetrix SNP arrays to study aberrations in 369 acute lymphoblastic leukemias (ALL) and controls. Of these, 127 were matched samples representing the active phase of disease (cancer) and remission phase ("normal"). Interestingly, 15.3% of the active phase samples exhibited loss of the miR-101-2 locus (and only 1.2% exhibited loss of miR-101-1) ( fig. S18) . None of the matched controls (remission phase samples) displayed loss in either of the genomic loci confirming the somatic nature of this aberration. Furthermore, it is interesting to note that miR-101-2 loss does not occur frequently in the TEL-AML sub-type of ALL (fig. S18) the biological implications of which are unclear.
Overall, this study began with a search for miRNAs that might regulate EZH2 expression, an important mediator of epigenetic pathways in embryonic stem cells and malignant progression. While several miRNA candidates were nominated by computational algorithms, we show that experimentally only miR-101 directly regulates EZH2 expression and is inversely associated with EZH2 levels in cancer progression. miR-101 has properties consistent with that of a tumor suppressor gene that functions by negatively regulating the oncogenic potential of EZH2. Furthermore, miR-101, by virtue of its regulation of EZH2, may have profound control over the epigenetic pathways active not only in cancer cells, but in normal pluripotent embryonic stem cells. We demonstrated that overexpression of miR-101 decreases the level of trimethyled histone H3K27 in cancer cells and presumably can configure the histone code of cancer cells to more of a benign phenotype. Presumably miR-101 is a functional regulator of the PRC2 complex and is expressed at high levels in differentiated cells and at low levels in embryonic stem cells and subsets of more aggressive cancers leading to EZH2 and PRC2 induction. Importantly, we discovered a genetic mechanism for EZH2 elevation in cancer that involves the somatic loss of the miR-101 genomic loci. Similar to EZH2 being broadly elevated in subsets of cancers, our meta-analysis revealed that the miR-101 genomic loci is lost in a subset of different cancer types. As the loss of miR-101 and concomitant elevation of EZH2 is most pronounced in metastatic cancer, we postulate that miR-101 loss may represent a progressive molecular lesion in the development of more aggressive disease. Approaches to re-introduce miR-101 into tumors may have therapeutic benefit by reverting the epigenetic program of tumor cells to a more normal state. 
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